All In Biotech

Drug Trial Radar · NCT05410535

To Evaluate Efficacy of Ursodeoxycholic Acid (UDCA) for the Prevention of Gallstone Formation After Gasterectomy

A Multi-center, Phase IV, Extension Study in PEGASUS-D Trial to Evaluate Efficacy of Ursodeoxycholic Acid (UDCA) for the Prevention of Gallstone Formation After Gastrectomy in Patients With Gastric Cancer

Last checked: Nov 20, 2026Latest source record: Jun 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 431 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

431

Actual

Start

Sep 15, 2021

Primary completion

Oct 28, 2022

Study completion Oct 28, 2022

Sponsor

Sponsor type
Industry
First posted
Jun 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Of those patients who participated in PEGASUS-D FAS clinical trial, patient must sign the informed consent form in order to participate in this extension study. The medical records of the patients will be reviewed throughout the study.

Conditions

  • Gastric Cancer

Interventions

  • Patients who continued UDCA 300mg medicationDrug

    patients who continued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial

  • Patients who discontinued UDCA 300mg prescriptionOther

    patients who discontinued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects with gallstones formedTime frame: at 3 years
  2. Proportion of subjects with gallstones formedTime frame: at 5 years
  3. The incidence of symptomatic gallstones, acute cholecystitis, cholangitis, pancreatitis, liver abscess, and cholecystectomy.Time frame: at 3 years
  4. The incidence of symptomatic gallstones, acute cholecystitis, cholangitis, pancreatitis, liver abscess, and cholecystectomy.Time frame: at 5 years
  5. The duration of UDCATime frame: up to 5 years
  6. The dose of UDCATime frame: up to 5 years
  7. The recurrence rate of gastric cancerTime frame: up to 5 years
  8. The survival rate of gastric cancerTime frame: up to 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • DoJoong Park

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.